Skin Aging Stack: 7-Compound Longevity Protocol
A multi-lane stack pairing topical copper peptides and a healing blend with systemic NAD⁺ precursors and Khavinson bioregulators (Vilon, Regeno, Thymalin, Epitalon).
What's in the Stack
Glycyl-histidyl-lysine + Cu(II) — the most extensively studied copper tripeptide for skin. Modulates wound healing, collagen / decorin synthesis, antioxidant defenses, and gene expression linked to dermal repair. Topical use is the primary cosmetic delivery. (PMID 26236730, 18644225)
A compounded blend pairing BPC-157 (angiogenic, granulation) and TB-500 / Thymosin β4 (cell migration, matrix remodeling) with GHK-Cu — used for accelerated cutaneous repair around procedures. BPC-157 wound-healing evidence base is reviewed in PMID 34267654.
NAD⁺ is a sirtuin/PARP substrate that declines with age and limits DNA-damage response and mitochondrial function. NMN and NR have measurable RCT evidence for safely raising NAD⁺ in middle-aged adults. (PMID 26785480, 37619764, 36482258)
Short peptide bioregulators (Vilon=KE, Regeno=skin complex, Thymalin=thymus complex, Epitalon=AEDG) developed in the Russian/Soviet Khavinson school. Proposed mechanism: tissue-specific gene-expression modulation; KE + AEDG both modulate SIRT1/PARP and ribosomal protein expression. (PMID 14666197, 37782636, 33342107, 12937682)
What the Data Shows
Daily Dosing Schedule
Key Takeaways
- GHK-Cu has the broadest peer-reviewed evidence base in this stack — multi-pathway skin regeneration data spans decades (PMID 26236730, 18644225).
- NMN raises NAD⁺ in middle-aged adults safely in placebo-controlled trials (PMID 36482258); NAD⁺ aging biology is a Science-level consensus framework (PMID 26785480).
- KE (Vilon) modulates SIRT1 / PARP gene expression in aging human MSCs in vitro (PMID 37782636); AEDG (Epitalon) and KE both affect pineal/thymus senescent cell biology (PMID 33342107).
- Epitalon induces telomerase activity in human somatic cells in vitro (PMID 12937682) — the foundational Khavinson telomere study.
- Thymalin raises the mature T-cell marker CD28 ~6.8× in HSC culture (PMID 33237528) — relevant because immunosenescence drives skin inflammation.
- Distinct lanes (topical / oral / SC) minimize overlap and let the user titrate one variable at a time.
- No randomized human trial has tested this 7-compound stack as a unit — synergy is mechanistic and additive, not proven.
- Regeno, Vilon, Thymalin, and Epitalon are NOT FDA-approved; most evidence is rodent, in vitro, or Russian/post-Soviet clinical literature.
- NMN status in the US is unsettled — FDA has signaled NMN is excluded from the dietary-supplement definition; sourcing and legality may shift.
- Khavinson protocols are short cycles (not daily for life). Most published dosing is per-cycle, with breaks between.
- Topical GHK-Cu skin reactions are uncommon but real (contact irritation, transient flushing) — patch-test before full-face application.
- No verified human PK data for SC Khavinson dipeptides at the doses commonly sold to consumers — extrapolating IM clinical doses to home SC use is not supported.
Frequently Asked Questions
Why combine 7 compounds instead of just GHK-Cu or just NMN?
Skin aging is driven by overlapping but distinct mechanisms: collagen / matrix loss (addressed by GHK-Cu and BPC-157/TB-500), NAD⁺ decline (NMN), telomere shortening (Epitalon), immunosenescence (Thymalin), and gene-expression drift in aging stem cells (Vilon, Regeno). A stack lets each lane target a different mechanism rather than stacking three of the same.
Is this stack FDA-approved?
No. GHK-Cu is widely used in cosmetic skincare (not FDA-approved as a drug). NMN is sold as a supplement, but its FDA status is unsettled. BPC-157 / TB-500 / Vilon / Regeno / Thymalin / Epitalon are research peptides — not FDA-approved drugs. Treat the entire stack as research, not medical therapy.
What is the safest single compound to start with?
Topical GHK-Cu has the deepest cosmetic safety record and the broadest peer-reviewed mechanistic literature (PMID 26236730). Starting with a once-daily topical lets you assess tolerability before adding systemic agents.
How do Vilon, Regeno, Thymalin, and Epitalon differ?
All four are short-peptide "bioregulators" from the Russian Khavinson school but target different tissues: Vilon (KE / Lys-Glu) — thymus and broad gene-expression modulator; Regeno — skin-derived complex; Thymalin — multi-peptide thymus extract (active dipeptides KE + EW); Epitalon (AEDG / Ala-Glu-Asp-Gly) — pineal tetrapeptide associated with telomerase and circadian effects. All are dosed in short cycles, not continuously.
Will this reverse wrinkles?
Honest answer: no single compound in this stack has a randomized human trial showing wrinkle reversal as a primary endpoint. The mechanistic case for GHK-Cu in skin remodeling is strong; the systemic Khavinson + NAD⁺ lanes target aging biology upstream of visible skin changes. Expect incremental improvements in skin texture, hydration, and recovery — not dramatic morphologic reversal.
Can I run all 7 at once?
Not recommended for a first cycle. Layering 7 novel compounds simultaneously makes it impossible to identify the cause of any adverse reaction. A safer sequence: (1) GHK-Cu topical for 4–8 weeks; (2) add NMN oral; (3) add one Khavinson SC cycle (Thymalin OR Epitalon) for 10 days; (4) iterate. Always with bloodwork before, during, and after.
🔬 Research-Grade Source
Swiss Chems publishes third-party HPLC COAs for every batch. HighPeptides' primary vendor reference for peptides.
Browse Swiss Chems →Affiliate link — supports HighPeptides at no extra cost
🛒 Recommended Products
Support supplements and gear relevant to this protocol.
Affiliate links — support HighPeptides at no extra cost.
📚 Related HighPeptides Research
Educational purposes only. Not medical advice.
No randomized human trial has tested this 7-compound stack as a unit.
Several stack components (Vilon, Regeno, Thymalin, Epitalon, BPC-157, TB-500) are NOT FDA-approved research peptides — not recognized medicines in the US, EU, or UK.
Do not stack 7 novel compounds simultaneously without bloodwork, baseline labs, and provider oversight.